There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

The FTC's long-awaited report on pharmacy benefit managers is out, and makes uncomfortable reading for the pharma supply chain middlemen.

Health Secretary Robert F. Kennedy Jr. looks poised to win the battle over fluoride, to the dismay of dentists and oral ...

Just before President Trump pushed her out at the behest of his corporate donors, former Federal Trade Commission chairwoman Lina Khan released a damning report about the most rapacious and ...

The Federal Trade Commission (FTC), charged with protecting the American consumer, on January 15, 2025, issued a special ...

An Iowa business group has joined up with some health insurance plans and employers in the state to challenge a new local law that regulates pharmacy benefit managers, saying it will drive up ...

Healthcare analyst Ellen Andrews, Ph. D, highlights a first-in-the-nation bill that the state passed this year in an effort to control generic drug prices.

Five days later, Cole had a severe asthma attack, stopped breathing and collapsed. According to his family, he suffered ...

The FTC said it's doled out more than $126 million in refunds to Fortnite players who were charged for unwanted purchases, an amount that represents roughly half of the agreed upon $245 million ...

PBMs appeal FTC case over insulin costs The FTC alleges anticompetitive and unfair rebating practices that artificially inflate the list price of insulin.

The Federal Trade Commission (FTC) is issuing more refunds to players of Epic Games "Fortnite." ...